Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, et al.
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...
Silsarma A, Iyer AS, Galindo MA, Chavan VV, Khan Su, et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION Bedaquiline (BDQ) and linezolid (LZD) are Group A drugs and form part of shorter and longer BDQ-based regimens under India’s National Tuberculosis (TB) Programme. A syst...
Dhakulkar S, Das M, Sutar N, Oswal V, Shah D, et al.
2021-02-18 • PLOS One
2021-02-18 • PLOS One
BACKGROUND Childhood and adolescent drug-resistant TB (DR-TB) is one of the neglected infectious diseases. Limited evidence exists around programmatic outcomes of children and adoles...
Mansoor H, Hirani N, Chavan VV, Das M, Sharma J, et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND In high TB burden countries, access to drug susceptibility testing is a major bottleneck. Targeted next-generation sequencing (tNGS) is a promising technology for rapid re...
Chavan VV, Dalal A, Nagaraja SB, Thekkur P, Mansoor H, et al.
2020-06-16 • PLOS One
2020-06-16 • PLOS One
Background
Imipenem, an intravenous antibiotic is recommended for use in drug resistant tuberculosis (DR-TB) when an effective regimen with combination of other second line drugs is...
Mansoor H, Hirani N, Chavan VV, Joshi A, Oswal V, et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION In countries with a high tuberculosis (TB) burden, poor access to drug susceptibility testing is a major bottleneck in diagnosing drug-resistant (DR) TB. India is estima...
